Budesonide use and misuse in sports: elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Coll Camenforte, Sergi, 1991-
- dc.contributor.author Monfort Mercader, Núria, 1983-
- dc.contributor.author Matabosch Geronès, Xavier
- dc.contributor.author Papakonstantinou, Katerina
- dc.contributor.author Pérez Mañá, Clara
- dc.contributor.author Mateus Rodriguez, Julian Andrés
- dc.contributor.author Ventura Alemany, Rosa
- dc.date.accessioned 2020-05-06T07:07:38Z
- dc.date.issued 2020
- dc.description.abstract Budesonide (BUD) is a glucocorticoid (GC) widely used in therapeutics. In sports, the World Anti-doping Agency (WADA) controls the use of GCs, and WADA-accredited laboratories use a reporting level of 30 ng/mL for 6β-hydroxy-budesonide (6βOHBUD) to detect the systemic administration of BUD. In the present work, we examined the urinary excretion profile of 6βOHBUD, BUD, and 16α-hydroxy-prednisolone (16αOHPRED) after intranasal (INT), inhaled (INH) (at high doses) and oral administrations in male and female volunteers. BUD was administered to healthy volunteers using INT route (256 μg/day for three days, n = 4 males and 4 females), INH route (800 μg/day for three days, n = 4 males and 4 females, and 1600 μg/day for three days, n = 4 males) or oral route (3 mg, n = 8 females). Urine samples were collected before and after administration at different time periods, and were analyzed by liquid chromatography-tandem mass spectrometry. 6βOHBUD and BUD concentrations were very low after INT treatment (0.0-7.1 and 0.0-8.1 ng/mL, respectively), and higher after INH treatments (0.0-35.4 and 0.0-48.3 ng/mL, respectively). For 16αOHPRED, elevated concentrations were detected after INT and INH treatments (2.6-66.4 and 3.4-426.5 ng/mL, respectively). Concentrations obtained following oral administration were higher than after therapeutic administrations (2.8-80.6, 1.5-36.1, and 10.4-532.2 ng/mL for 6βOHBUD, BUD, and 16αOHPRED, respectively). After all administrations, concentrations were higher in males than in females. Results demonstrated that 6βOHBUD is the best discriminatory marker and a reporting level of 40 ng/mL was found to be the best criterion to distinguish allowed from forbidden administrations of BUD.
- dc.format.mimetype application/pdf
- dc.identifier.citation Coll S, Monfort N, Matabosch X, Papakonstantinou K, Pérez-Mañá C, Mateus JA, et al. Budesonide use and misuse in sports: elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations. Drug Test Anal. 2020 May; 12(5):629-36. DOI: 10.1002/dta.2678
- dc.identifier.doi http://dx.doi.org/10.1002/dta.2678
- dc.identifier.issn 1942-7603
- dc.identifier.uri http://hdl.handle.net/10230/44418
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Drug Testing and Analysis. 2020 May;12(5):629-36
- dc.rights This is the peer reviewed version of the following article: [Coll S, Monfort N, Matabosch X, Papakonstantinou K, Pérez-Mañá C, Mateus JA, et al. Budesonide use and misuse in sports: elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations. Drug Test Anal. 2020 May; 12(5):629-36, which has been published in final form at http://dx.doi.org/10.1002/dta.2678. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Budesonide
- dc.subject.keyword Doping
- dc.subject.keyword Reporting level
- dc.title Budesonide use and misuse in sports: elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion